Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
02/2001
02/14/2001EP1075267A2 Treatment of celiac disease
02/14/2001EP1075266A1 Hematopoietic stimulation
02/14/2001EP1075265A1 Use of tetracyclines for treating meibomian gland disease
02/14/2001EP1075264A1 New drug combinations of a n.a.r.i., preferably reboxetine, and pindolol
02/14/2001EP1075263A1 Aqueous process for manufacturing paroxetine solid dispersions
02/14/2001EP1075262A1 Desmethylpantoprazole compositions and methods
02/14/2001EP1075261A1 Mycobacterial inhibitors
02/14/2001EP1075260A2 Novel fatty acid analogues for the treatment of primary and secondary restenosis
02/14/2001EP1075259A1 Novel fatty analogues for the treatment of diabetes
02/14/2001EP1075258A1 Novel fatty analogues for the treatment of obesity, hypertension and fatty liver
02/14/2001EP1075257A1 Use of triclosan for the treatment of helicobacter pylori infections
02/14/2001EP1075256A1 Arylhydrocarbon receptor ligand antagonists
02/14/2001EP1075255A1 Inhibition of binding of hox and homeodomain-containing proteins and uses thereof
02/14/2001EP1075254A2 The use of polyamines in the treatment of dermatological symptoms
02/14/2001EP1075191A1 Phytosterol compositions
02/14/2001EP1075186A1 Method of hsv prophylaxis
02/14/2001EP0994743A4 Treatment of inflammatory disorders of the bowel and urinary bladder
02/14/2001EP0968226A4 G-rich oligo aptamers and methods of modulating an immune response
02/14/2001EP0844874A4 METHODS AND COMPOSITIONS USEFUL FOR INHIBITION OF ALPHA v BETA 5 MEDIATED ANGIOGENESIS
02/14/2001EP0842170B1 Diphenylmethylene piperidine derivatives
02/14/2001EP0833820B1 Benzisoxazole and indazole derivatives as antipsychotic agents
02/14/2001EP0828714B1 Method for making quinolone carboxylic acids or naphthyridine carboxylic acids in free base form
02/14/2001EP0815120B1 17-difluoromethylene-oestratrienes
02/14/2001EP0773964B1 Gas phase production of polydienes
02/14/2001EP0714897B1 Fused heteroaromatic cyclopentene derivative having endothelin-antagonist activity
02/14/2001EP0643071B1 Compound for inhibiting bone resorption and accelerating osteogenesis
02/14/2001EP0607198B1 Preparation of improved alkylpolyglycoside surfactant mixtures
02/14/2001CN1284134A Methods of producing anti-angiogenic proteins: endostation, angiostation or restin, using pichia yeast expression system
02/14/2001CN1284130A Mutants of endostation, 'EM1' having ant-angiogenic activety and methods of use thereof
02/14/2001CN1284081A Novel macrolides compounds
02/14/2001CN1284079A Novel compounds
02/14/2001CN1284078A Heterocycilc compounds for inhibition of gastric acid secretion, processes for their prepn. and pharmaceutical compsns thereof
02/14/2001CN1284077A Purine derivatives having phosphodiesterase IV inhibition activity
02/14/2001CN1284076A 2-aryl-8-oxodihydropurine derivatives, process for producting same, medicinal conty. same, and intermediates thereof
02/14/2001CN1284074A Novel compounds
02/14/2001CN1284073A 5-(2-imidazolinylamino)-benzimidazole derivatives, their prepn. and their use as alpha-adrenoceptor agonists with inproved metabolic stability
02/14/2001CN1284072A Prodrugs of aspartyl protease inhibitors
02/14/2001CN1284071A Sulphona mide derivatives as prodrugs of aspartyl protease inhibitors
02/14/2001CN1284066A Substituted inidazole derivatives having agonist-like activity at alpha 2B or 2B/2C adrenergic receptors
02/14/2001CN1284064A 2,3-substituted indole compounds as cox-2 inhibitors
02/14/2001CN1284060A Novel metalloproteinase inhibitors
02/14/2001CN1284059A Biphenylamidine derivatives
02/14/2001CN1284058A Neuroprotective agents
02/14/2001CN1284057A Adamantane derivatives
02/14/2001CN1284056A Anticonvulsant and sentral nervous system-active bis (fluorophenyl) alkylamides
02/14/2001CN1283996A Method/thiol biochdes
02/14/2001CN1283995A Antiviral compounds
02/14/2001CN1283994A Methods for treatment of neuro-and nephro-disorders and therapeutic toxicities using aminothiol compounds
02/14/2001CN1283993A Method for producing solid dosing forms
02/14/2001CN1283992A Sustained release drug delivery device
02/14/2001CN1283991A Soft-pellet drug and process for prepn, thereof
02/14/2001CN1283990A Long cating injectable formulations contg. hydrogenated castor oil
02/14/2001CN1283983A Improved personal formulations
02/14/2001CN1283633A Carboxynethylated derivative of ganoderic alpha-(1-3)-D-glucosan and its usage and preparing process
02/14/2001CN1283632A Ganoderic alpha-(1-3)-D-glucosan sulfate derivative and its usage and preparing process
02/14/2001CN1283624A Process for preparing 'Xidinafei' medicine
02/14/2001CN1283623A 1,2,4,5-tetrahydro-benzo[d] azepine compound
02/14/2001CN1283622A 6-hydroxy-3(4-[2-(piperidine-1-group)oxyethyl group]phenoxy)-2-(4-methoxy phenyl) benzo[b] thiophene hydrochloride salt
02/14/2001CN1283488A Medicinal composition for treating alopesia
02/14/2001CN1283483A Anticancer capsule 'Wushensu' and its extracting and preparing process
02/14/2001CN1283482A Medicinal composition for treating cardiovascular disease and its preparing process
02/14/2001CN1283480A Medicine for treating piles
02/14/2001CN1283478A 'Yidaosheng' capsules
02/14/2001CN1283473A Medicine for treating cardiovascular and cerebrovascular apoplexy and applexy aurae and its preparing process
02/14/2001CN1283469A Compound tablet 'Changning' and its preparing process
02/14/2001CN1283468A Compound tablet 'Changning' and its preparing process
02/14/2001CN1283466A Powdered medicine 'Kouqiangyanhousan' and its preparing process
02/14/2001CN1283464A High-molecular medicine resisting tumor metastasis and its preparing process
02/14/2001CN1283463A Process for preparing solid-state-microspherical vascular suppository of sodium alginate
02/14/2001CN1283462A Application of astragalin A in preparing medicinal composition
02/14/2001CN1283461A Antiparasitic pre-mixture containing evericin, ivermection or acetylamino evericin for fish, shrimp and crab
02/14/2001CN1283460A Application of respiratory chain buiquinone depressant in preventing thrombolytic reperfusion damage
02/14/2001CN1283459A Medicine for curing bronchial asthma and asthmatic chronic bronchitis and its preparing process
02/14/2001CN1283458A Compound dihydroartemisinin as new antimalarial
02/14/2001CN1283457A Medicine for treating hircus
02/14/2001CN1283456A Compound for treating cancers of mammal
02/14/2001CN1283455A Application of black fading hormone and black fading ligand in medicinal compsns for prevention and treatment of gastrointestional tract disease
02/14/2001CN1283454A Method for preparing pellet contg fat-soluble substances
02/14/2001CN1283451A Local compsn, contg, tocopherol
02/14/2001CN1283447A Locally-used weight reducing face-care compsns.
02/14/2001CN1283418A Compound chitosane for additive for discharging lead
02/14/2001CN1283413A Skin-care agent, health and face-care foodstuff
02/14/2001CN1061983C 4-trifluoromethyl-3-ketosteroid compound and synthesizing method thereof
02/14/2001CN1061977C Aryl substituted heterocycles
02/14/2001CN1061859C Medicine for treating hircismus
02/14/2001CN1061855C Compound drug for treating rheumatism
02/14/2001CN1061844C External-use antithyroid cream
02/13/2001USRE37053 Particles incorporating surfactants for pulmonary drug delivery
02/13/2001US6187944 A phenyl acrylonitrile compounds useful as active ingredients of an insecticide, a miticide, a nematicide, a soil pesticide, a fungicide and a marine antifouling agent
02/13/2001US6187933 Bind to retinoid receptors; treating skin disorders
02/13/2001US6187932 Subjecting n-(d-alpha-methyl-beta-acylthiopropionyl)-l-proline to hydrolysis reaction in aqueous medium in presence of strong acid at specified temperature to remove acyl group, isolating captopril
02/13/2001US6187930 Reacting selected amine with optically active acid selected from (+)-ditoluyl-l-tartaric acid and/or (-)-ditoluyl-l-tartaric acid in solvent to form diasteroisomeric salt, separating, isolating enantiomer
02/13/2001US6187905 Peptide compound which inhibits viral proteinases; viricides for hepatitis c, hepatitis g, and human gb viruses
02/13/2001US6187822 To inhibit adenosine diphosphate-ribosylation of vascular endothelial growth factor, wherein the enzyme inhibitor is selected from vitamin k1, vitamin k3, novobiocin, and silybin; healing wounds such as diaper dermatitis
02/13/2001US6187820 Administering compounds such as n,n-dimethyl-1-(1-(4-chlorophenyl)cyclobutyl)-3-methylbutylamine hydrochloride for prophylaxis or treatment of hyperlipidemia, hypercholesterolemia or hypertriglyceridemia
02/13/2001US6187819 Protein kinase C activators and their use in decreasing expression of cell antigens
02/13/2001US6187818 Prostaglandins formulation and process
02/13/2001US6187817 Preventing or reducing ototoxicity in a human, cat or dog by administering d-methionine free of the l-isomer
02/13/2001US6187815 Topically applying procaine and niacin in given dosage amount in a topical hydrophilic vehicle
02/13/2001US6187814 By topically an farnesoid x-activated receptor (fxr) activator selected from farnesal, alkyl farnesyl ether, alkyl farnesoate, and 7-methyl-9-(3,3-dimethyloxiranyl)-3-methyl-2,6-nonadienoic acid, alkyl ester